Verdonk et al. “Docking performance of fragments and drug-like compounds.” Journal of Medicinal Chemistry 54, no. 15 2011: 5422–5431. DOI: 10.1021/jm200558u.

/in ,

Verdonk et al. “Docking performance of fragments and drug-like compounds.” Journal of Medicinal Chemistry 54, no. 15 2011: 5422–5431. DOI: 10.1021/jm200558u.

Williams, Glyn. “The pyramid approach to fragment-based biophysical screening.” In Label-Free Technologies for Drug Discovery, edited by Matthew Cooper and Lorenz M. Mayr, 241-253. Chichester, UK: John Wiley & Sons Ltd 2011. ISBN: 978-0-470-74683-7.

/in ,

Williams, Glyn. “The pyramid approach to fragment-based biophysical screening.” In Label-Free Technologies for Drug Discovery, edited by Matthew Cooper and Lorenz M. Mayr, 241-253. Chichester, UK: John Wiley & Sons Ltd 2011. ISBN: 978-0-470-74683-7.

Yap et al. “Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930.” Molecular Cancer Therapeutics 10, no. 2 2011: 360-71. DOI: 10.1158/1535-7163.MCT-10-0760.

/in ,

Yap et al. “Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930.” Molecular Cancer Therapeutics 10, no. 2 2011: 360-71. DOI: 10.1158/1535-7163.MCT-10-0760.